Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Discrepancies in therapeutic indications for the same oncology drugs among FDA, EMA, and Brazilian agency.

View Full Paper
Ask AI
Bookmark
Share

Authors

CBCamila Marchi BlattMMMário Henrique Furlanetto MirandaRBRafael Balsini Barreto

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Blatt et al. (2024) studied this question.

synapsesocial.com/papers/68e67050b6db6435875fa65ahttps://doi.org/10.1200/jco.2024.42.16_suppl.e23035
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Review of All Solid Tumor Drug Approvals From 2019 to 2024 by US Food and Drug Administration, European Medicines Agency, and Brazilian Health Regulatory Agency2025 · 2 citations
  2. 2Regulatory Approval of New Oncology Drugs, 2020–2024: A Comparative Analysis of FDA, EMA, and ANVISA2026
  3. 3New Oncologic Drugs from 2008 to 2023—Differences in Approval and Access between the United States, Europe and Brazil2024 · 5 citations
  4. 4Time until Oncologic Treatment Approval in Brazil Compared to Europe and the United States2026
  5. 5Marketing Authorisations with Limited Clinical Evidence: A Review of Small-Scale Cancer Drug Studies2026